| (210) | Number of the EPO application | 21798552 |
| (220) | Filing date of the EPO application | 2021.10.13 |
| (80) | EPO patent specification publication (B) | EPB nr. 31/2025, 2025.07.30 |
| (110) | EPO patent number | 4228753 |
| (21) | Number of the application | e 2023 0823 |
| (71) | Name(s) of applicant(s), code of the country | Qilu Regor Therapeutics Inc., CN; |
| (72) | Name(s) of inventor(s), code of the country | ZHONG Wenge, US;
GUO Wei, CN;
LI Zheng Jane, US;
JIANG Xiawei, CN;
CHEN Pengyuan, CN; |
| (73) | Name(s) of owner(s), code of the country | Qilu Regor Therapeutics Inc., CN; |
| (54) | Title of the invention | CRYSTAL FORMS OF GLP-1R AGONISTS AND USES THEREOF |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61P 3/10 (2006.01.01); C07D 405/14 (2006.01.01); A61K 31/4439 (2006.01.01) |
| (19) | Country | CN |
| (41) | Date of publication of the application | 2023.09.30 |
| (30) | Priority | PCT/CN2020/1208, 2020.10.14, WO |
| (86) | International application | PCT/CN2021/123387, 2021.10.13 |
| (87) | International publication | WO 2022/078352, 2022.04.21 |